https://www.nasdaq.com/press-release/axonicsr-ceo-raymond-w.-cohen-receives-lifetime-entrepreneurial-achievement-award-by
https://www.nasdaq.com/press-release/axonicsr-ranked-the-fastest-growing-company-in-north-america-on-the-2021-deloitte
https://www.nasdaq.com/press-release/deloitte-unveils-2021-north-america-technology-fast-500-rankings-2021-11-17
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-piper-sandler-virtual-healthcare-conference-2021-11-08
https://www.nasdaq.com/press-release/axonicsr-reports-third-quarter-2021-financial-results-2021-11-04
https://www.nasdaq.com/press-release/axonicsr-ranked-the-fastest-growing-publicly-traded-company-in-orange-county-2021-10
https://www.nasdaq.com/press-release/axonicsr-to-report-third-quarter-2021-financial-results-on-november-4-2021-10-07
https://www.nasdaq.com/press-release/axonicsr-provides-additional-update-on-inter-partes-review-proceedings-2021-09-22
https://www.nasdaq.com/press-release/u.s.-patent-and-trademark-office-rejects-axonics-challenge-to-medtronic-patents-2021
https://www.nasdaq.com/press-release/axonicsr-announces-partial-decision-on-inter-partes-review-proceedings-2021-09-13
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-upcoming-investor-conferences-2021-08-27
https://www.nasdaq.com/press-release/axonicsr-reports-second-quarter-2021-financial-results-2021-08-05
https://www.nasdaq.com/press-release/bioventrix-announces-raymond-w.-cohen-as-chairman-of-the-board-and-newly-appointed
https://www.nasdaq.com/press-release/axonicsr-announces-appointment-of-dr.-esteban-lopez-to-its-board-of-directors-2021-07
https://www.nasdaq.com/press-release/biolife-solutions-announces-changes-to-board-of-directors-2021-07-14
https://www.nasdaq.com/press-release/axonicsr-to-report-second-quarter-2021-financial-results-on-august-5-2021-2021-07-08
https://www.nasdaq.com/press-release/axonicsr-files-pma-supplement-with-the-fda-for-non-rechargeable-implantable-sacral
https://www.nasdaq.com/press-release/axonicsr-receives-fda-approval-further-expanding-mri-labeling-2021-05-20
https://www.nasdaq.com/press-release/axonicsr-announces-ce-mark-approval-for-implantable-sacral-neurostimulator-that
https://www.nasdaq.com/press-release/axonicsr-announces-closing-of-public-stock-offering-and-full-exercise-of-0
https://www.nasdaq.com/press-release/axonicsr-announces-upsize-and-pricing-of-public-offering-of-common-stock-2021-05-13
https://www.nasdaq.com/press-release/axonicsr-announces-proposed-public-offering-of-common-stock-2021-05-13
https://www.nasdaq.com/press-release/axonicsr-reports-first-quarter-2021-financial-results-2021-05-06
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-the-bofa-securities-2021-virtual-healthcare-conference
https://www.nasdaq.com/press-release/axonicsr-to-report-first-quarter-2021-financial-results-on-may-6-2021-2021-04-15
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-the-barclays-global-healthcare-conference-2021-03-03
https://www.nasdaq.com/press-release/endotronix-appoints-industry-veteran-dan-dearen-to-board-of-directors-2021-03-02
https://www.nasdaq.com/press-release/axonicsr-announces-strategic-alliance-for-the-manufacture-of-new-non-rechargeable
https://www.nasdaq.com/press-release/axonicsr-reports-fourth-quarter-and-fiscal-year-2020-results-2021-02-25
https://www.nasdaq.com/press-release/axonicsr-expands-into-stress-urinary-incontinence-with-the-acquisition-of-bulkamidr
https://www.nasdaq.com/press-release/axonicsr-to-report-fourth-quarter-and-fiscal-year-2020-financial-results-on-february
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-the-society-for-urodynamics-female-pelvic-medicine
https://www.nasdaq.com/press-release/axonicsr-receives-fda-approval-for-third-generation-implantable-neurostimulator-2021
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-the-svb-leerink-global-healthcare-conference-2021-02-11
https://www.nasdaq.com/press-release/axonicsr-reports-preliminary-fourth-quarter-and-fiscal-year-2020-revenue-2021-01-25
https://www.nasdaq.com/press-release/axonicsr-announces-appointment-of-david-m.-demski-to-board-of-directors-2020-12-14
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-piper-sandler-virtual-healthcare-conference-2020-11-19
https://www.nasdaq.com/press-release/axonicsr-announces-publication-of-fecal-incontinence-study-results-for-patients
https://www.nasdaq.com/press-release/axonicsr-reports-third-quarter-2020-results-2020-11-04
https://www.nasdaq.com/press-release/axonicsr-submits-pma-supplement-to-fda-to-further-expand-mri-labeling-2020-10-29
https://www.nasdaq.com/press-release/axonicsr-launches-artistry-study-to-collect-and-analyze-real-world-data-of-patients
https://www.nasdaq.com/press-release/axonicsr-to-report-third-quarter-2020-results-on-november-4-2020-10-14
https://www.nasdaq.com/press-release/axonicsr-ceo-raymond-w.-cohen-named-ernst-young-entrepreneur-of-the-yearr-2020-0
https://www.nasdaq.com/press-release/axonicsr-announces-survey-results-of-patients-treated-with-the-axonics-r-snm-system
https://www.nasdaq.com/press-release/axonicsr-provides-update-on-inter-partes-review-proceedings-2020-09-24
https://www.nasdaq.com/press-release/axonicsr-receives-health-canada-approval-of-next-generation-implantable
https://www.nasdaq.com/press-release/axonicsr-ceo-raymond-w.-cohen-named-ernst-young-entrepreneur-of-the-yearr-2020-award
https://www.nasdaq.com/press-release/axonicsr-reports-2-year-clinical-results-from-artisan-snm-pivotal-study-2020-09-10
https://www.nasdaq.com/press-release/nice-recommends-axonicsr-r-snm-system-for-treating-overactive-bladder-2020-09-08
https://www.nasdaq.com/press-release/axonicsr-to-participate-in-upcoming-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/axonicsr-to-host-presentation-of-full-2-year-clinical-results-from-artisan-snm
https://www.nasdaq.com/press-release/axonicsr-reports-second-quarter-2020-results-2020-08-06
https://www.nasdaq.com/press-release/axonicsr-announces-2-year-topline-clinical-results-from-artisan-snm-pivotal-study
https://www.nasdaq.com/press-release/axonicsr-to-report-second-quarter-2020-results-on-august-6-2020-07-16
https://www.nasdaq.com/press-release/axonicsr-reports-preliminary-second-quarter-2020-revenue-2020-07-13
https://www.nasdaq.com/press-release/axonicsr-receives-fda-approval-for-3t-full-body-mri-scans-2020-07-01
https://www.nasdaq.com/press-release/axonicsr-artisan-results-published-demonstrating-continued-therapy-response-and
https://www.nasdaq.com/press-release/axonicsr-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters
https://www.nasdaq.com/press-release/axonicsr-announces-pricing-of-public-offering-of-common-stock-2020-05-07
https://www.nasdaq.com/press-release/axonicsr-announces-proposed-public-offering-of-common-stock-2020-05-07
https://www.nasdaq.com/press-release/axonicsr-reports-first-quarter-2020-results-2020-05-05
https://www.nasdaq.com/press-release/axonicsr-names-michael-h.-carrel-as-chairman-of-its-board-of-directors-2020-04-29
https://www.nasdaq.com/press-release/axonicsr-announces-u.s.-food-drug-administration-approval-of-next-generation
https://www.nasdaq.com/press-release/axonicsr-to-present-at-the-needham-healthcare-conference-2020-04-08
https://www.nasdaq.com/press-release/axonicsr-to-report-first-quarter-2020-financial-results-on-may-5-2020-04-07
https://www.nasdaq.com/press-release/axonicsr-submits-pma-supplement-to-u.s.-food-drug-administration-to-expand-full-body
https://www.nasdaq.com/press-release/axonicsr-announces-filing-of-petitions-before-the-united-states-patent-and-trademark
https://www.nasdaq.com/press-release/axonicsr-announces-fourth-quarter-and-fiscal-2019-financial-results-2020-03-04
https://www.nasdaq.com/press-release/axonicsr-to-present-at-the-barclays-global-healthcare-conference-2020-02-25
https://www.nasdaq.com/press-release/axonicsr-to-report-2019-fourth-quarter-and-full-year-financial-results-and-host-a
https://www.nasdaq.com/press-release/axonicsr-to-present-at-the-svb-leerink-global-healthcare-conference-2020-02-11
https://www.nasdaq.com/press-release/axonicsr-sacral-neuromodulation-system-receives-reimbursement-approval-in-germany
https://www.nasdaq.com/press-release/axonicsr-announces-fda-approval-of-enhanced-neurostimulator-programmer-2020-01-21
https://www.nasdaq.com/press-release/axonicsr-announces-preliminary-fourth-quarter-and-full-year-2019-revenue-2020-01-09
https://www.nasdaq.com/press-release/axonicsr-granted-six-u.s.-patents-and-allowed-three-additional-patents-related-to-its
https://www.nasdaq.com/press-release/axonicsr-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares
https://www.nasdaq.com/press-release/axonicsr-provides-survey-results-from-physician-seminar-series-showcasing-the
https://www.nasdaq.com/press-release/health-canada-approves-full-body-mri-labeling-for-the-axonicsr-sacral-neuromodulation
https://www.nasdaq.com/press-release/axonicsr-to-present-at-upcoming-investor-conferences-2019-11-26
https://www.nasdaq.com/press-release/sanford-health-now-implanting-axonicsr-sacral-neuromodulation-systems-2019-11-25
https://www.nasdaq.com/press-release/axonicsr-announces-closing-of-%24110-million-public-offering-of-common-stock-2019-11-22
https://www.nasdaq.com/press-release/axonicsr-announces-agreement-to-supply-its-sacral-neuromodulation-system-to-the
https://www.nasdaq.com/press-release/axonicsr-announces-pricing-of-public-offering-of-common-stock-2019-11-19
https://www.nasdaq.com/press-release/axonicsr-announces-proposed-public-offering-of-common-stock-2019-11-19
https://www.nasdaq.com/press-release/axonicsr-announces-third-quarter-2019-financial-results-and-operational-update-2019
https://www.nasdaq.com/press-release/axonicsr-announces-u.s.-food-drug-administration-approval-for-its-sacral-0
https://www.nasdaq.com/press-release/axonicsr-to-report-2019-third-quarter-and-nine-month-financial-results-and-host-a
https://www.nasdaq.com/press-release/axonicsr-responds-to-patent-action-by-medtronic-2019-11-05
https://www.nasdaq.com/press-release/axonicsr-announces-first-commercial-u.s.-patient-implanted-with-its-sacral
https://www.nasdaq.com/press-release/axonicsr-provides-update-on-u.s.-launch-activities-2019-10-15
https://www.nasdaq.com/press-release/axonicsr-broadens-eu-commercial-footprint-with-recommendation-for-reimbursement-in
https://www.nasdaq.com/press-release/axonicsr-provides-full-one-year-results-from-artisan-snm-pivotal-study-at-augs-iuga
